Business Context and Reporting Period
This Form 8-K, dated November 17, 2017, reports material events for Cerecor Inc. (noting a discrepancy in the request metadata referencing "Avalo Therapeutics, Inc."). The filing details the consummation of two major acquisitions and significant changes to the company's executive leadership and Board of Directors.
Key Financial Metrics and Transaction Details
The filing discloses specific financial terms for two completed transactions on November 17, 2017:
- Acquisition of TRx Pharmaceuticals, LLC: Total consideration included $18.9 million in cash (subject to working capital and other adjustments) and common stock valued at $4.1 million on the closing date. Contingent payments may also apply.
- Merger with Zylera Pharma Corp.: Consideration consisted of common stock valued at $4.0 million on the closing date, transferred to the sellers.
- Total Equity Issuance: Approximately $8.1 million in aggregate value of unregistered common stock was issued in connection with these transactions.
- Financial Statements: The filing does not provide current revenue, profit, cash flow, or debt metrics for Cerecor Inc. Financial statements for the acquired businesses and pro forma information are scheduled to be filed within 71 days.
Material Changes
The primary material changes reported are:
- Asset Expansion: Cerecor Inc. acquired 100% of the equity interests of TRx Pharmaceuticals, LLC and merged Zylera Pharma Corp. into a wholly-owned subsidiary.
- Leadership Restructuring:
- Robert C. Moscato, Jr. was appointed President, Chief Operating Officer, and a Class I Director.
- Interim CEO John Kaiser and Chief Medical Officer Dr. Ronald Marcus resigned effective November 21, 2017.
- Randal O. Jones was appointed a Class III Director and received an initial stock option grant for 16,714 shares.
Outlook, Risks, and Contingencies
Management Commentary: The appointments of Mr. Moscato and Mr. Jones are intended to leverage their extensive experience in the healthcare and pharmaceutical industries, particularly in product launches and sales force development.
Risks and Contingencies:
- Indemnification: The Purchase and Merger Agreements include provisions requiring Cerecor to indemnify the sellers for losses resulting from breaches of representations, warranties, or covenants.
- Unregistered Securities: The stock issued for the acquisitions was not registered under the Securities Act of 1933, relying on Section 4(a)(2) exemptions.
- Future Filings: Investors must await the filing of financial statements for the acquired businesses and pro forma financial information to assess the full financial impact.
Investor Verification Checklist
- Verify the exact terms of the "Estimated Working Capital," "Estimated Cash on Hand," and "Estimated Indebtedness" adjustments in the TRx Pharmaceuticals purchase agreement to determine the final cash consideration.
- Review the forthcoming financial statements of TRx Pharmaceuticals and Zylera Pharma (due within 71 days) to assess the revenue and cash flow contribution of the new assets.
- Confirm the vesting schedule and valuation of the stock options granted to new Director Randal O. Jones.
- Monitor for the appointment of a permanent Chief Executive Officer following the resignation of the interim CEO.